Clinical trial
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
NCT00237718 · Vanderbilt University, Other · Completed
Key facts
| NCT number | NCT00237718 |
|---|---|
| Title | Provision of Antioxidant Therapy in Hemodialysis (PATH) Study |
| Official title | Provision of Antioxidant Therapy in Hemodialysis (PATH) Study |
| Lead sponsor | Vanderbilt University, Other |
| Collaborators | Fresenius Medical Care North America Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | End-stage Renal Disease |
| Intervention type | Drug |
| Interventions | Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo |
| Enrollment | 385 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Oct 12, 2005 |
| Last update posted | Jan 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: